Cao Zhongqin – Trademark Portfolio
Entity Type: 01
Cao Zhongqin owns a portfolio of 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as GRAJOY, NECAOL, ADEOJOY, AMISPER, and LEXASKY. Of these, 5 are registered. The portfolio spans 5 Nice Classification classes, led by Class 5 (Pharmaceuticals) and Class 25 (Clothing). Headquartered in Maoming City.
Yuntan Town, Gaozhou City
No. 120, Lizhupo Village
Maoming City 525246 , CN
Showing of trademarks Trademarks
Trademark Classifications
Cao Zhongqin's trademark portfolio spans 5 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Precious metals and their alloys; jewellery, precious stones; horological instruments
Paper and cardboard; printed matter; bookbinding material; photographs; stationery
Frequently Asked Questions
How many trademarks does Cao Zhongqin have?
Cao Zhongqin has 6 U.S. trademarks filed with the USPTO. Of these, 5 registered, 1 abandoned.
What trademark classes does Cao Zhongqin file in?
Cao Zhongqin files trademarks across 5 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 25 (Clothing), Class 3 (Cosmetics & Cleaning), Class 14 (Jewelry), Class 16 (Paper Goods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Cao Zhongqin's most well-known trademarks?
Cao Zhongqin's registered trademark portfolio includes well-known marks such as GRAJOY, NECAOL, ADEOJOY, AMISPER, and LEXASKY. These are among 5 currently registered trademarks in the portfolio.
What is Cao Zhongqin's trademark registration success rate?
Cao Zhongqin has a 83% trademark registration rate, with 5 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.